Investment case
SK Biopharmaceuticals Co., Ltd.
SKBPF · 3 developments mapped · last assessed 2026-08-28
Market Ontology has mapped 3 macro, policy, and market developments to SK Biopharmaceuticals Co., Ltd. since 2026-08-26. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for SKBPF yet, so no modelled value is shown. The SKBPF valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run SKBPF on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Biohaven partners with SK Biopharmaceuticals in $795M licensing deal
Expansion of pipeline and potential for future revenue streams.
· Moves future revenue growth from new pipeline assets, r&d efficiency and strategic pipeline expansion
- Open question
Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
Strategic pipeline expansion and potential future revenue streams, balanced by upfront investment.
· Moves future cash flows, probability of success pipeline
What changed, by assumption
- 2026-08-28Biohaven partners with SK Biopharmaceuticals in $795M licensing deal
- 2026-08-28Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
- 2026-08-26SK Biopharmaceuticals Co., Ltd. to Acquire Biohaven Ltd. ($795M)
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-28 | Biohaven partners with SK Biopharmaceuticals in $795M licensing deal | Bullish | 3-12m | 0.60 |
| 2026-08-28 | Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim | mixed | 3-12m | 0.60 |
| 2026-08-26 | SK Biopharmaceuticals Co., Ltd. to Acquire Biohaven Ltd. ($795M) | mixed | 3-12m | 0.60 |